Wound dressings as growth factor delivery platforms for chronic wound healing
| Autor: | Joshua S. Boateng, Ovidio Catanzano, Fabiana Quaglia |
|---|---|
| Přispěvatelé: | Catanzano, O., Quaglia, F., Boateng, J. S. |
| Rok vydání: | 2021 |
| Předmět: |
Chronic wound
medicine.medical_specialty Pharmaceutical Science 02 engineering and technology wound dressing Q1 030226 pharmacology & pharmacy nanotechnologie Bandage 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Intercellular Signaling Peptides and Protein medicine Humans In patient Intensive care medicine chronic wound Wound Healing Tissue Engineering integumentary system business.industry growth factor 021001 nanoscience & nanotechnology Bandages Wound dressing drug delivery Intercellular Signaling Peptides and Proteins medicine.symptom 0210 nano-technology Wound healing business Human |
| Zdroj: | Expert Opinion on Drug Delivery. 18:737-759 |
| ISSN: | 1744-7593 1742-5247 |
| DOI: | 10.1080/17425247.2021.1867096 |
| Popis: | Introduction: Years of tissue engineering research have clearly demonstrated the potential of integrating growth factors (GFs) into scaffolds for tissue regeneration, a concept that has recently been applied to wound dressings. The old concept of wound dressings that only take a passive role in wound healing has now been overtaken, and advanced dressings which can take an active part in wound healing, are of current research interest.\ud \ud Areas covered: In this review we will focus on the recent strategies for the delivery of GFs to wound sites with an emphasis on the different approaches used to achieve fine tuning of spatial and temporal concentrations to achieve therapeutic efficacy.\ud \ud Expert opinion: The use of GFs to accelerate wound healing and reduce scar formation is now considered a feasible therapeutic approach in patients with a high risk of infections and complications. The integration of micro – and nanotechnologies into wound dressings could be the key to overcome the inherent instability of GFs and offer adequate control over the release rate. Many investigations have led to encouraging outcomes in various in vitro and in vivo wound models, and it is expected that some of these technologies will satisfy clinical needs and will enter commercialization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|